Skip to main content
. Author manuscript; available in PMC: 2024 Nov 29.
Published in final edited form as: Mol Pharm. 2023 Aug 8;20(9):4629–4639. doi: 10.1021/acs.molpharmaceut.3c00360

Figure 4.

Figure 4.

PET/CT images at 24, 48, and 72 h postinjection of a HER2-positive tumor-bearing mouse (SUVmean scale 0.3–2). The tumor can be clearly visualized on the left shoulder of the mouse at all time points in both the maximum intensity projection (MIP) and transverse slice images.